ICAM2

ICAM2, also known as Intercellular Adhesion Molecule 2, is a type I transmembrane glycoprotein that plays a crucial role in cell adhesion and immune response. It belongs to the ICAM family, which includes proteins that bind to leukocyte adhesion LFA-1 protein. ICAM2 is involved in lymphocyte recirculation and mediating adhesive interactions for antigen-specific immune response and NK-cell mediated clearance. It is also associated with innate immune system and CLEC7A (Dectin-1) signaling pathways. ICAM2 is linked to various diseases, including colon and intestine carcinomas, and is being investigated as a potential prognostic marker and therapeutic target in cancer immunotherapy.
Recent research has shown that ICAM2 expression is downregulated in gastric cancer (GC) and is associated with disease progression and poor prognosis. Overexpression of ICAM2 suppresses GC cell proliferation, migration, invasion, and tumor formation, suggesting its potential as a therapeutic target. Additionally, ICAM2 is involved in the ubiquitination and degradation of RDX protein, which may contribute to the inhibition of GC. Further investigation into ICAM2's role in cancer and its potential as a therapeutic target is ongoing.